Richard Bran­son takes 23andMe pub­lic with his SPAC, as the Glax­o­SmithK­line part­ner aims to beef up drug R&D

One of the buzzi­est names in health­care and de­liv­er­ing per­son­al­ized med­i­cine di­rect­ly based on a cus­tomer’s ge­net­ics went pub­lic Thurs­day, and used a high-pro­file bil­lion­aire …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER